https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52399 Tue 10 Oct 2023 18:07:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35993 Thu 23 Jan 2020 14:49:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20771 vs as-needed 1·05, 0·92–1·20). We recorded no difference between treatment groups for time to recovery (adjusted p=0·79). Adherence to regular tablets (median tablets consumed per participant per day of maximum 6; 4·0 [IQR 1·6–5·7] in the regular group, 3·9 [1·5–5·6] in the as-needed group, and 4·0 [1·5–5·7] in the placebo group), and number of participants reporting adverse events (99 [18·5%] in the regular group, 99 [18·7%] in the as-needed group, and 98 [18·5%] in the placebo group) were similar between groups. Interpretation: Our findings suggest that regular or as-needed dosing with paracetamol does not affect recovery time compared with placebo in low-back pain, and question the universal endorsement of paracetamol in this patient group.]]> Sat 24 Mar 2018 08:00:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20056 Sat 24 Mar 2018 08:00:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27312 Sat 24 Mar 2018 07:38:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27393 Sat 24 Mar 2018 07:34:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52344 50 years of age versus > 70 years of age) across different studies, as this has previously been shown to influence results.]]> Mon 09 Oct 2023 14:57:37 AEDT ]]>